| Medical and Health Sciences | Lifetime | 340 | CN 4 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 62 | CN 5 | 99.99 |
| Pulmonary and Respiratory Medicine | Lifetime | 18 | CN 1 | 99.97 |
| Oncology | Lifetime | 58 | CN 1 | 99.90 |
| Cancer Research | Lifetime | 279 | CN 19 | 98.35 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 5 | CN 2 | 99.97 |
| Oncology | 2021-2025 | 22 | CN 2 | 99.88 |
| Cancer Research | 2021-2025 | 40 | CN 18 | 98.35 |
| Surgery | 2021-2025 | 841 | CN 74 | 92.51 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 515 | CN 53 | 89.35 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 3 | CN 1 | 99.96 |
| Lung Cancer Treatments and Mutations | Lifetime | 5 | CN 1 | 99.96 |
| Lung Cancer Research Studies | Lifetime | 3 | CN 1 | 99.95 |
| Colorectal Cancer Treatments and Studies | Lifetime | 10 | CN 1 | 99.90 |
| Cancer Genomics and Diagnostics | Lifetime | 76 | CN 4 | 99.78 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 66 | CN 2 | 99.80 |
| Gastric Cancer Management and Outcomes | Lifetime | 176 | CN 5 | 99.48 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 255 | CN 18 | 99.06 |
| Cancer therapeutics and mechanisms | Lifetime | 125 | CN 3 | 99.18 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 188 | CN 9 | 99.04 |
| Ferroptosis and cancer prognosis | Lifetime | 192 | CN 81 | 97.51 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 169 | CN 5 | 98.48 |
| HER2/EGFR in Cancer Research | Lifetime | 299 | CN 2 | 98.70 |
| Brain Metastases and Treatment | Lifetime | 330 | CN 3 | 97.72 |
| Cancer Mechanisms and Therapy | Lifetime | 565 | CN 96 | 94.68 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 1 | CN 1 | 99.97 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 4 | CN 1 | 99.97 |
| Lung Cancer Research Studies | 2021-2025 | 6 | CN 2 | 99.92 |
| Cancer Genomics and Diagnostics | 2021-2025 | 35 | CN 1 | 99.60 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 54 | CN 8 | 99.78 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 30 | CN 3 | 99.51 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 80 | CN 17 | 99.10 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 143 | CN 24 | 96.87 |
| Ferroptosis and cancer prognosis | 2021-2025 | 231 | CN 184 | 96.24 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 693 | CN 210 | 95.72 |
| HER2/EGFR in Cancer Research | 2021-2025 | 199 | CN 22 | 96.91 |
| Peptidase Inhibition and Analysis | 2021-2025 | 383 | CN 95 | 92.88 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 904 | CN 112 | 94.43 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 83 | CN 12 | 89.98 |
| Brain Metastases and Treatment | 2021-2025 | 410 | CN 9 | 90.37 |
| Cancer Research and Treatments | 2021-2025 | 752 | CN 316 | 80.87 |
| Cancer therapeutics and mechanisms | 2021-2025 | 714 | CN 109 | 76.44 |
